Nationwide Fund Advisors Maintains Holdings in ChemoCentryx, Inc. (CCXI)
Nationwide Fund Advisors held its stake in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 13,828 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Nationwide Fund Advisors’ holdings in ChemoCentryx were worth $129,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also made changes to their positions in CCXI. Renaissance Technologies LLC lifted its stake in ChemoCentryx by 31.0% during the 1st quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock valued at $4,489,000 after acquiring an additional 146,000 shares during the period. BB&T Securities LLC acquired a new stake in ChemoCentryx during the 2nd quarter valued at approximately $781,000. Vanguard Group Inc. lifted its stake in ChemoCentryx by 4.1% during the 1st quarter. Vanguard Group Inc. now owns 1,198,730 shares of the biopharmaceutical company’s stock valued at $8,727,000 after acquiring an additional 47,475 shares during the period. Wedge Capital Management L L P NC acquired a new stake in ChemoCentryx during the 2nd quarter valued at approximately $424,000. Finally, ClariVest Asset Management LLC acquired a new stake in ChemoCentryx during the 2nd quarter valued at approximately $390,000. Institutional investors and hedge funds own 49.21% of the company’s stock.
ChemoCentryx, Inc. (NASDAQ CCXI) opened at $7.32 on Monday. ChemoCentryx, Inc. has a 12 month low of $6.13 and a 12 month high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. equities research analysts expect that ChemoCentryx, Inc. will post -0.67 earnings per share for the current fiscal year.
Several brokerages have commented on CCXI. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Tuesday, October 10th. Finally, ValuEngine cut shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. ChemoCentryx has an average rating of “Hold” and an average price target of $8.25.
TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/20/nationwide-fund-advisors-maintains-holdings-in-chemocentryx-inc-ccxi.html.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).
Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.